Boston Scientific Corporation

Boston Scientific Corporation is a global medical technology leader headquartered in Marlborough, Massachusetts. Founded in 1979 by John Abele and Peter Nicholas, the company has grown into one of the world's largest medical device manufacturers with US$20.074 billion in 2025 revenue, approximately 59,000 employees, and a presence in 130+ countries.

Core Business

Boston Scientific operates across seven core interventional medical specialties: Interventional Cardiology, Structural Heart, Peripheral Interventions, Cardiac Rhythm Management, Electrophysiology, Endoscopy, and Urology/Pelvic Health. The company's category leadership strategy has produced category-defining products including the WATCHMAN FLX left atrial appendage closure device (dominant market share), the FARAPULSE pulsed field ablation system (early leadership in next-gen AFib therapy), the AGENT drug-coated balloon (first FDA-approved coronary DCB), and the SpyGlass DS cholangioscopy platform. The company generates approximately 85% of revenue from single-use devices and implants, creating a highly recurring revenue model.

Global Presence

The company operates 25+ manufacturing and distribution facilities across the United States, Ireland, Costa Rica, Malaysia, and other key locations. With approximately 59,000 employees globally, Boston Scientific serves customers in 130+ countries, with the United States representing approximately 58% of revenue and international markets contributing 42%. The company has been investing aggressively in emerging markets with double-digit growth in Asia-Pacific (particularly China and India) and expanding its manufacturing footprint in Penang, Malaysia and other cost-advantaged locations.

Key Strengths

Boston Scientific has established itself as the fastest-growing large-cap medical device company, consistently delivering double-digit organic revenue growth since 2022 — outpacing peers by a wide margin. The WATCHMAN franchise enjoys near-monopoly positioning in left atrial appendage closure with limited direct competition. The FARAPULSE system represents early market leadership in the pulsed field ablation segment, a major paradigm shift in atrial fibrillation treatment. The company's strategic acquisition program (Axonics, Silk Road Medical, Bolt Medical) has systematically expanded its total addressable market into adjacent interventional categories.

VerityRank Score

VerityRank Score of 89/100